CAJ | 학술논문

目的：分析老年冠心病患者经皮冠状动脉介入治疗（PCI）术后应用雷贝拉唑的安全性。方法选取2011年3月—2012年11月在安庆市第一人民医院心血管内科住院的老年冠心病患者120例（年龄≥60岁），随机分为对照组和雷贝拉唑组，每组60例。两组患者均接受 PCI，并于术前、术后口服阿司匹林、氯吡格雷及冠心病治疗药物，雷贝拉唑组患者在 PCI 术后口服雷贝拉唑钠肠溶胶囊，20 mg/ d。观察两组患者上消化道不良反应发生情况，PCI 术后3、6个月大便隐血试验阳性率，PCI 术后6个月、1年主要复合终点发生情况。结果两组患者均获得随访，无一例失访，无一例死亡。雷贝拉唑组患者上消化道不良反应发生率，PCI 术后3、6个月大便隐血试验阳性率均低于对照组（P ＜0.01）；两组患者 PCI 术后6个月、1年主要复合终点发生率比较，差异无统计学意义（P ＞0.05）。结论雷贝拉唑有助于减少老年冠心病患者 PCI 术后上消化道不良反应、消化道出血的发生，且不增加其不良临床结局的发生风险，安全性较高。
목적：분석노년관심병환자경피관상동맥개입치료（PCI）술후응용뢰패랍서적안전성。방법선취2011년3월—2012년11월재안경시제일인민의원심혈관내과주원적노년관심병환자120례（년령≥60세），수궤분위대조조화뢰패랍서조，매조60례。량조환자균접수 PCI，병우술전、술후구복아사필림、록필격뢰급관심병치료약물，뢰패랍서조환자재 PCI 술후구복뢰패랍서납장용효낭，20 mg/ d。관찰량조환자상소화도불량반응발생정황，PCI 술후3、6개월대편은혈시험양성솔，PCI 술후6개월、1년주요복합종점발생정황。결과량조환자균획득수방，무일례실방，무일례사망。뢰패랍서조환자상소화도불량반응발생솔，PCI 술후3、6개월대편은혈시험양성솔균저우대조조（P ＜0.01）；량조환자 PCI 술후6개월、1년주요복합종점발생솔비교，차이무통계학의의（P ＞0.05）。결론뢰패랍서유조우감소노년관심병환자 PCI 술후상소화도불량반응、소화도출혈적발생，차불증가기불량림상결국적발생풍험，안전성교고。
Objective To analyze the safety of rabeprazole in elderly coronary heart disease patients treated by percu- taneous coronary intervention(PCI). Methods From March 2011 to November 2012,120 coronary heart disease patients aged over 60 years old were selected in the Department of Cardiology,the First People's Hospital of Anqing,and they were randomly divided into control group and rabeprazole group,60 cases in each. Both groups underwent PCI and given aspirin,clopidogrel, coronary heart disease drug therapy before and after PCI,rabeprazole group received extra rabeprazole sodium enteric - coated capsules after PCI,20 mg per night. The incidence of upper gastrointestinal adverse reactions,positive rate of fecal occult blood testing three months and six months after PCI,incidence of composite endpoint six months and one year after PCI between the two groups were compared. Results All of the patients were followed - up,and no one died. The incidence of upper gastrointestinal adverse reactions,positive rate of fecal occult blood testing three months and six months after PCI of rabeprazole group were lower than those of control group(P < 0. 01);no significant differences was found of incidence of composite endpoint six months and one year after PCI between the two groups(P > 0. 05). Conclusion Rabeprazole is helpful to reduce the incidence of upper gastrointestinal adverse reactions and alimentary tract hemorrhage in elderly coronary heart disease patients treated by PCI,with- out increasing the incidence of adverse clinical outcome,and is safe.